
October 19, 2020

Listing Department
BSE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai – 400 001

Code: 532 321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 051

Code: CADILAHC

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated October 19, 2020 titled "**Zydus Cadila receives tentative approval from USFDA for Tofacitinib Extended-Release Tablets**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus Cadila receives tentative approval from USFDA for Tofacitinib Extended-Release Tablets

Ahmedabad, 19 October, 2020

Zydus Cadila has received tentative approval from the USFDA to market Tofacitinib Extended-Release Tablets, 11 mg (US RLD: Xeljanz XR[®] Tablets). It is recommended for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis (UC).

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 308 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

For further information please contact :
The Corporate Communications Department

Cadila Healthcare Limited
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.
Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com
CIN : L24230GJ1995PLC025878